These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8755013)

  • 21. [Effect of alpha inhibitors on risk cofactors in patients with hypertension].
    Plouin P
    Ann Cardiol Angeiol (Paris); 1989 Dec; 38(9 Pt 2):577-9; discussion 580. PubMed ID: 2576348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of three antihypertensive drug groups on lipid metabolism. Effects of alpha receptor blockers, central sympatholytic drugs and vasodilators].
    Jacob BG; Richter WO; Schwandt P
    Fortschr Med; 1993 Mar; 111(8):126-9. PubMed ID: 8099558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension, insulin, and alpha 1-blockade.
    Weidmann P; Ferrari P
    J Clin Pharmacol; 1993 Sep; 33(9):895-9. PubMed ID: 7901245
    [No Abstract]   [Full Text] [Related]  

  • 24. [The treatment of hypertension in patients with a metabolic disorder].
    Dal Palù C; Semplicini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():130S-132S. PubMed ID: 8562259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Is antihypertensive treatment a risk factor of coronary disease? Therapy-related triglyceride increase nor diabetes increase the risk].
    Samuelsson O; Pennert K; Andersson O; Berglund G; Hedner T; Persson B; Wedel H; Wilhelmsen L
    Lakartidningen; 1998 Mar; 95(11):1120-3. PubMed ID: 9542820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of antihypertensive therapy on the hemodynamics of hypertension: clinical implications.
    Lund-Johansen P
    Clin Ther; 1986; 8(4):382-97. PubMed ID: 3524841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of antihypertensive therapy on glucose and lipid metabolism.
    Zehetgruber M; Christ G; Mundigler G; Gabriel H; Huber K
    Wien Klin Wochenschr; 1996 Dec; 108(24):775-80. PubMed ID: 9017889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hypertension management in general practice in Iceland].
    Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G
    Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium channel blockers and coronary heart disease.
    Inzitari M; Di Bari M; Marchionni N
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):6-15. PubMed ID: 16640169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Interference with lipid metabolism by various antihypertensive agents: facts and hypotheses].
    Rouffy J
    Arch Mal Coeur Vaiss; 1987 Apr; 80 Spec No():43-6. PubMed ID: 2887148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
    Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
    Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New and emerging strategies for reducing cardiometabolic risk factors.
    Rodgers PT; Fuke DC
    Pharmacotherapy; 2006 May; 26(5 Pt 2):13S-31S; quiz 43S-45S. PubMed ID: 16637783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study).
    Olkinuora JT; Viikari J; Vanhanen H; Makkonen N; Kalliomäki T
    Scand Cardiovasc J; 2006 Jun; 40(3):160-6. PubMed ID: 16798663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension in obesity.
    Redon J
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):344-53. PubMed ID: 11887431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review.
    Weidinger G
    Arzneimittelforschung; 1995 Nov; 45(11):1166-71. PubMed ID: 8929232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
    Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.